



56879

**BRAWN BIOTECH LTD.**

Date: 29<sup>th</sup> May 2026

The General Manager  
The Department of Corporate Services,  
BSE Limited, 25th Floor,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai -400001

BSE Scrip Code: 530207  
Scrip ID: BRAWN

**Sub: Outcome of the Board Meeting of the Company held on 29<sup>th</sup> May 2026, and submissions of Audited Financial Results for the Quarter and year ended 31.03.2026.**

Ref: Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (SEBI Listing regulations).

Dear Sir/Ma'am,

With reference to the captioned subject and pursuant to the provisions of Regulation 30 and Regulation 33 of SEBI Listing Regulations, this is to inform you that the Board of Directors of the Company in its meeting held today, 29<sup>th</sup> May 2026 has considered and approved the Audited Financial Results along with Audit Report by the Company's Statutory Auditor for the Quarter and year ended 31.03.2026, a Copy of which is enclosed herewith.

We wish to further inform you that the meeting of the board of directors commenced at 3:30 P.M. and concluded at 4:00 P.M.

Kindly take the same on your record and acknowledge receipt of the same.

Thanking You.

For and on behalf of  
Brawn Biotech Limited

*Priyanka*



Priyanka Sharma  
Company Secretary and Compliance Officer  
Membership No.: A50385  
Encl: As above

**BRAWN BIOTECH LTD.****CIN NO.: L74899DL1985PLC022468**

Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331

Email: solution@brawnbiotech.com

Works : Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA

Email: distribution@brawnlabs.in | Website : www.brawngroup.in

*...for better life*



IF563

**BRAWN BIOTECH LTD.**

BRAWN BIOTECH LIMITED CIN:L74899DL1985PLC022468 REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024						
STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2026						
					Rs. In Lacs	
Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-Mar-26 Un-audited	31-Dec-25 Un-audited	31-Mar-25 Un-audited	31-Mar-26 Audited	31-Mar-25 Audited
1	<b>Revenue from operations</b>					
	Revenue from operations	197.65	431.26	577.20	1,697.77	1,346.50
	Other Income	18.09	9.10	45.19	45.40	9.33
	<b>Total Revenue</b>	<b>215.74</b>	<b>440.36</b>	<b>622.39</b>	<b>1,743.18</b>	<b>1,355.83</b>
2	<b>Expenses</b>					
a	Cost of material consumed	-	-	-	-	-
b	Purchase of stock-in-trade	130.12	353.63	91.39	1,411.44	1,638.05
c	Change in inventories of finished goods, work in progress and stock in trade	41.32	14.77	362.69	40.49	(445.04)
d	Employee Benefit expenses	19.21	14.08	(21.78)	68.36	112.63
e	Depreciation and amortisation expenses	3.00	3.03	3.87	12.20	11.46
f	Finance Cost	0.23	0.01	0.26	0.45	0.37
g	Other expenses	57.48	49.86	55.46	210.13	218.17
	<b>Total Expenses</b>	<b>251.36</b>	<b>435.37</b>	<b>491.89</b>	<b>1,743.07</b>	<b>1,535.64</b>
3	<b>Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)</b>	(35.62)	4.98	130.50	0.11	(179.81)
4	<b>Other Income</b>	-	-	-	-	-
5	<b>Profit from ordinary activities before exceptional items (3-4)</b>	(35.62)	4.98	130.50	0.11	(179.81)
6	<b>Exceptional Items</b>	-	-	-	-	-
7	<b>Profit from ordinary activities before tax (5-6)</b>	(35.62)	4.98	130.50	0.11	(179.81)
8	<b>Tax Expenses</b>	(93.95)	-	-	(93.95)	-
9	<b>Profit (Loss) for the period from continuing operations (7-8)</b>	58.34	4.98	130.50	94.06	(179.81)
10	<b>Profit/(loss) from discontinuing operations</b>	-	-	-	-	-
11	<b>Tax expense of discontinuing operations</b>	-	-	-	-	-
12	<b>Profit/(loss) from Discontinuing operations (after tax) (10-11)</b>	-	-	-	-	-
13	<b>Profit (Loss) for the period (9+12)</b>	58.34	4.98	130.50	94.06	(179.81)
14	<b>Other Comprehensive Income</b>	0.08	0.02	(0.16)	3.65	3.73
	<b>Total Comprehensive Income</b>	58.41	5.00	130.35	97.71	(176.08)
15	Details of equity share capital	300.03	300.03	300.03	300.03	300.03
	Paid-up equity share capital					
	Face value of equity share capital					
16	Reserve excluding Revaluation Reserve					
17	Earnings per share					
i	Basic earnings per share	1.95	0.17	4.34	3.26	(5.87)
ii	Diluted earnings per share	1.95	0.17	4.34	3.26	(5.87)

**NOTES :-**

- Results for the quarter and year ended on 31st March, 2026 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 29th May, 2026.
- The Statutory Auditors carried out the audit for year ended 31st March, 2026. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone audited Financial Results for the quarter and year ended ended on 31-03-2025 are available on company's website [www.brawnbiotech.com](http://www.brawnbiotech.com) and BSE website [www.bseindia.com](http://www.bseindia.com).
- Figures for the quarter ended 31st March 2026 are the differences between the figures for the year ended 31st March 2026 and Nine month ended 31st December 2025.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board  
For Brawn Biotech Limited

*(Signature)*  
Brji Raj Gupta  
Director  
DIN NO. 00974969  
Date: 29.05.2026  
Place: Delhi

**BRAWN BIOTECH LTD.****CIN NO.: L74899DL1985PLC022468****Works :** Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA  
Email: [distribution@brawnlabs.in](mailto:distribution@brawnlabs.in) | Website : [www.brawngroup.in](http://www.brawngroup.in)**Regd. Office :** C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com)

...for better life



23337

**BRAWN BIOTECH LTD.**

BRAWN BIOTECH LIMITED CIN:L74899DL1985PLC022468 REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024 Extract of Standalone Audited Financial Results for the quarter and year ended 31st March 2026 (Rs. In Lacs)				
Sr. No	Particulars	Standalone		
		Quarter ended 31-03-2026	Year ended 31-03-2026	Year ended 31-03-2025
		Un-audited	Audited	Audited
1	Total income from operation	215.74	1,743.18	1,355.83
2	Net Profit/(Loss) from ordinary activities after tax	58.34	94.06	(179.81)
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	58.34	94.06	(179.81)
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	58.41	97.71	(176.08)
5	Equity Share Capital	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)	-	-	-
7	Earning per share (before extraordinary items)(not annualised): (of rs. 10 each)	-	-	-
	(a) Basic (Rs.)	1.95	3.26	(5.87)
	(b) Diluted (Rs.)	1.95	3.26	(5.87)
8	Earning per share (after extraordinary items)(not annualised): (of rs. 10 each)	-	-	-
	(a) Basic (Rs.)	1.95	3.26	(5.87)
	(b) Diluted (Rs.)	1.95	3.26	(5.87)

**NOTES :-**

- The above is an extract of the detailed format of Quarterly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly financial results are available on the Stock Exchange website ([www.bseindia.com](http://www.bseindia.com)) and on the company's website ([www.brawnbiotech.com](http://www.brawnbiotech.com)).
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 29-05-2026
- The Financials has been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ins-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01st April 2017 with transition date of 01st April, 2016.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- Figures for the quarter ended 31st March 2026 are the differences between the figures for the year ended 31st March 2026 and Nine month ended 31st December 2025.
- Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board  
For Brawn Biotech Limited

Brij Raj Gupta  
Director  
DIN NO. 00974969

Place: Delhi  
Date: 29.05.2026

**BRAWN BIOTECH LTD.****CIN NO.: L74899DL1985PLC022468****Works :** Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA  
Email: [distribution@brawnlabs.in](mailto:distribution@brawnlabs.in) | Website : [www.brawngroup.in](http://www.brawngroup.in)**Regd. Office :** C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com)*...for better life*



28D4E

**BRAWN BIOTECH LTD.**

BRAWN BIOTECH LIMITED CIN:L74899DL1985PLC022468 REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024		
Rs. in Lacs		
Statement of Assets and Liabilities as on 31st March 2026		
Particulars	31-Mar-26 Audited	31-Mar-25 Audited
<b>ASSETS</b>		
<b>(1) Non-Current Assets</b>		
Property, Plant, Equipment & Intangible Assets	36.47	46.04
Financial Assets		
-Investment		
- Trade Receivable	191.85	201.35
-Loan		
Deferred Tax Asset (Net)	145.41	51.46
<b>Total Non-Current Assets</b>	<b>373.73</b>	<b>298.85</b>
<b>(2) Current Assets</b>		
Inventories	1,006.21	1,046.70
Financial Assets		
- Trade Receivables	354.77	341.34
- Cash and cash equivalents	28.06	19.95
- Loan	1.32	1.93
- Other Financial Assets	127.77	119.67
Current Tax Assets (Net)	-	-
Other Current Assets	193.86	220.47
<b>Total Current Assets</b>	<b>1,711.99</b>	<b>1,750.05</b>
<b>TOTAL ASSETS</b>	<b>2,085.72</b>	<b>2,048.90</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity Share Capital	300.03	300.03
Other Equity	133.91	36.20
<b>TOTAL EQUITY</b>	<b>433.94</b>	<b>336.23</b>
<b>LIABILITIES</b>		
<b>(1) Non-current Liabilities</b>		
Financial Liabilities		
- Trade Payable	128.97	771.27
- Other Financial Liabilities		
Provisions	5.80	8.74
Deferred Tax liabilities (Net)		
<b>Total Non-Current Liabilities</b>	<b>134.77</b>	<b>780.01</b>
<b>(2) Current Liabilities</b>		
Financial Liabilities		
- Trade Payables	1,440.86	823.78
- Other Financial Liabilities	33.21	31.40
Other current liabilities	36.82	69.91
Provisions	6.12	7.58
Current tax liabilities		
<b>Total Current Liabilities</b>	<b>1,517.02</b>	<b>932.66</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>2,085.72</b>	<b>2,048.90</b>

For and on behalf of Board  
For Brawn Biotech Limited

  
Anil Raj Gupta  
Director  
DIN NO. 00974969  
Place : New Delhi  
Date: 29.05.2026

**BRAWN BIOTECH LTD.****CIN NO.: L74899DL1985PLC022468**

**Works :** Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA  
Email: [distribution@brawnlabs.in](mailto:distribution@brawnlabs.in) | Website : [www.brawngroup.in](http://www.brawngroup.in)

**Regd. Office :** C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com)

...for better life



30942



Brawn Biotech Limited  
Cash Flow Statement for the year ended 31st March, 2026  
CIN NO: L74899DL1985PLC022468

**BRAWN BIOTECH LTD.**

(Figures in Thousands)


Particulars	For the year ended		For the year ended	
	31.03.2026		31.03.2025	
<b>A. Cash flow from operating activities</b>				
Net Profit / (Loss) before extraordinary items and tax		10.80		(17,980.78)
<i>Adjustments for:</i>				
Profit of sale of Investment (Shares)			1,145.76	
Depreciation and amortisation	1,219.85		372.97	
Re-measurement losses on defined benefit plans	364.88			
Finance costs	44.51	1,629.24	36.56	1,555.28
Operating profit / (loss) before working capital changes		1,640.04		(16,425.49)
<i>Changes in working capital:</i>				
<i>Adjustments for (increase) / decrease in operating assets:</i>				
Inventories	4,048.63		(44,503.97)	
Trade receivables	(1,343.03)		4,696.81	
Long Term - Trade receivables	949.93		(13,542.51)	
Short-term loans and advances	1,911.51		(5,780.47)	
Long-term loans and advances			-	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>				
Trade payables	61,707.60		25,628.98	
Long Term - Trade payables	(64,230.42)		48,139.75	
Borrowings				
Other current liabilities	(3,308.20)		3,276.59	
Other financial liabilities	181.64		(668.71)	
Current tax liabilities				
Long-term provisions	(293.63)		(299.60)	
Short-term provisions	(145.50)	(521.48)	(47.12)	16,899.77
Cash flow from extraordinary items				
Cash generated from operations		1,118.57		474.28
Net income tax (paid) / refunds & Dividend				-
<b>Net cash flow from / (used in) operating activities (A)</b>		<b>1,118.57</b>		<b>474.28</b>
<b>B. Cash flow from investing activities</b>				
Capital expenditure on fixed assets, including capital advances	(262.34)		(2,416.12)	
Cash flow from extraordinary items				
<b>Net cash flow from / (used in) investing activities (B)</b>		<b>(262.34)</b>		<b>(2,416.12)</b>
<b>C. Cash flow from financing activities</b>				
Proceeds from long-term borrowings				
Proceeds from other short-term borrowings				
Finance cost	(44.51)		(36.56)	
Cash flow from extraordinary items				
<b>Net cash flow from / (used in) financing activities (C)</b>		<b>(44.51)</b>		<b>(36.56)</b>
<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>811.71</b>		<b>(1,978.40)</b>
Cash and cash equivalents at the beginning of the year		1,994.59		3,972.99
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents				
<b>Cash and cash equivalents at the end of the year</b>		<b>2,806.30</b>		<b>1,994.59</b>
<b>Reconciliation of Cash and cash equivalents with the Balance Sheet:</b>				
Cash and cash equivalents as per Balance Sheet (Refer Note- 8 )		2,806.30		1,994.59
Less: Bank balances not considered as Cash and cash equivalents				
Net Cash and cash equivalents		2,806.30		1,994.59
Add: Current investments considered as part of Cash and cash equivalents				
<b>Cash and cash equivalents at the end of the year *</b>		<b>2,806.30</b>		<b>1,994.59</b>
* Comprises:				
(a) Cash on hand		323.13		308.71
(b) Cheques, drafts on hand				
(c) Balances with banks				
(i) In current accounts		2,383.18		1,585.88
(ii) Bank deposit Accounts with more than 3 months maturity		100.00		100.00

**Notes:**

- (i) The Cash Flow Statement reflects the combined cash flows pertaining to continuing and discounting operations.  
(ii) These earmarked account balances with banks can be utilised only for the specific identified purposes.

Significant Accounting Policies &amp; Notes on Financial Statements

For and on behalf of Board of Directors

  
Brijraj Gupta  
(Director)  
DIN No. 00974969

Place: Delhi  
Date: 29.05.2026**CIN NO.: L74899DL1985PLC022468**

for better life

**Works :** Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIAEmail: [distribution@brawnlabs.in](mailto:distribution@brawnlabs.in) | Website: [www.brawngroup.in](http://www.brawngroup.in)**Regd. Office :** C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com)**BRAWN BIOTECH LTD.**



**Independent Auditor's Report on Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To  
The Board of Directors of  
Brawn Biotech Limited

**Report on the audit of the Standalone Financial Results**

**Opinion**

We have audited the accompanying statement of quarterly and year to date standalone financial results of Brawn Biotech Limited (the "Company") for the quarter ended March 31, 2026 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. are presented in accordance with requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2026 and for the year ended March 31, 2026.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Standalone Financial Results**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed



under section 133 of the Act read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional Skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Materiality is the magnitude of misstatements in the statement that, individually or in aggregate makes it probable that the economic decisions of a reasonably knowledgeable user of the statement may be influenced, we consider quantitative materiality and qualitative factors in (i) Planning the scope of our audit, work and in evaluating the results of our work; and (ii) to evaluate the effects of any identified misstatements in the statements
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
- We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matter

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of the full financial yearended March 31,2026 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations.

**For Rajiv Udai & Associates**  
**Chartered Accountants**  
**Firm Registration No. 18764N**

*Rajiv Jain*

**Rajeev Jain**  
**(Partner)**  
**Membership No.:099767**  
**UDIN:26099767VXCZCC9298**



**Place: Delhi**  
**Date:29-05-2026**



C67D3



**BRAWN BIOTECH LTD.**

**CFO CERTIFICATE UNDER REGULATION 33(2)(a) OF SEBI (LODR)  
REGULATION, 2015**

To  
The Board of Directors  
**Brawn Biotech Limited**  
First Floor, C-64 Lajpat Nagar-1,  
Delhi, 110024.

- A. I have reviewed Audited Financial Results of Brawn Biotech Limited for the quarter and year ended 31<sup>st</sup> March 2026 and to the best of my knowledge and belief that;
- a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
- b) These statements together present a true and fair view of the listed entity's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. There are, to the best of my knowledge and belief, no transactions entered into by the listed entity during the quarter and year ended 31<sup>st</sup> March 2026 which are fraudulent, illegal or violative of the listed entity's code of conduct.
- C. I have indicated to the Auditors and the Audit Committee that there are no significant changes in internal control over financial reporting during the quarter and the financial year and no instances of significant fraud with which they have become aware.

**For Brawn Biotech Limited**

**Rati Garg**  
**Chief Financial Officer**

Date: 29.05.2026  
Place: Delhi



**BRAWN BIOTECH LTD.**

**CIN NO.: L74899DL1985PLC022468**

**Works :** Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA  
Email: [distribution@brawnlabs.in](mailto:distribution@brawnlabs.in) | Website : [www.brawngroup.in](http://www.brawngroup.in)

**Regd. Office :** C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com)

*...for better life*



5759A

**BRAWN BIOTECH LTD.**

**CERTIFIED TRUE COPY OF THE RESOLUTION PASSED AT THE MEETING OF THE BOARD OF DIRECTORS OF BRAWN BIOTECH LIMITED HELD ON FRIDAY, 29<sup>th</sup> DAY OF MAY 2026 AT ITS REGISTERED OFFICE SITUATED AT C-64 LAJPAT NAGAR - 1, FIRST FLOOR, DELHI 110024, WHICH COMMENCED AT 3.30 PM AND CONCLUDED AT 4.00 PM**

**APPROVAL OF FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED ON 31<sup>ST</sup> MARCH 2026**

The draft Annual Financial Statements of the Company, comprising of Balance Sheet as at 31<sup>st</sup> March, 2026 and Statement of Profit and Loss and Cash Flow Statement for the financial year ended on 31<sup>st</sup> March 2026, together with notes were placed before Board for their consideration and approval.

Mr. Mayank Jain, the Chairman of the Audit Committee informed the Board that the members of Audit Committee in its meeting held on 29<sup>th</sup> May, 2026 today at registered office of the Company, considered the draft Annual Financial Statements for the financial year ended on 31<sup>st</sup> March, 2026 and recommended the same for consideration and approval of the Board.

After Discussion & deliberation, the following resolution has been passed by the Board unanimously:

**“RESOLVED THAT** pursuant to the provisions of Section 134 of the Companies Act, 2013 and any other applicable provisions of Companies Act, 2013 read with Rules made thereunder (including any statutory modifications or re-enactment thereof, for the time being in force), the Balance Sheet as on 31<sup>st</sup> March, 2026 and the Profit and Loss Account for the period ended on that date along with the Schedules, Notes thereto, Cash Flow Statements, of the Company, as placed before the board be and are hereby considered and approved.

**RESOLVED FURTHER THAT** Mr. Brij Raj Gupta, Director of the Company be and is hereby authorized to sign the Audited financial results for the quarter and year ended 31<sup>st</sup> March, 2026 and submit the same with stock exchange and other concerned authority.

**RESOLVED FURTHER THAT** the Annual Financial Statements including the Balance Sheet of the Company as at 31<sup>st</sup> March, 2026 and the Statement of Profit and Loss and Cash Flow Statement for the year ended 31<sup>st</sup> March, 2026 be signed by Mr. Brij Raj Gupta, Chairman of the Company, Ms. Pooja Jha, Director, Ms. Rati Garg, Chief Financial Officer and Ms. Priyanka Sharma, Company Secretary of the Company in accordance with the provisions of Section 134 of the Companies Act, 2013.

**RESOLVED FURTHER THAT** the Annual Financial Statements so signed be forwarded to the Statutory Auditors of the Company for their signatures and report thereon.”

For and on behalf of  
Brawn Biotech Limited

  
Priyanka Sharma  
Company Secretary & Compliance Officer.  
Membership No. A50385

Add: C-64 First Floor,  
Lajpat Nagar - 1, Delhi 110024.

**BRAWN BIOTECH LTD.****CIN NO.: L74899DL1985PLC022468****Regd. Office :** C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331

Email: solution@brawnbiotech.com

**Works :** Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA

Email: distribution@brawnlabs.in | Website : www.brawngroup.in

*...for better life*



59D23



**BRAWN BIOTECH LTD.**

**Date: 29<sup>th</sup> May 2026**

**The General Manager  
The Department of Corporate Services,  
BSE Limited, 25th Floor,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai -400001**

**BSE Scrip Code: 530207  
Scrip ID: BRAWN**

**Sub: Declaration under Regulation 33(3)(d) of Securities and Exchange Board of India  
(Listing Obligations and Disclosures Requirements) Regulations, 2015**

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended, we do hereby confirm that M/s Rajiv Udai & Associates, Chartered Accountants, the statutory auditors of the company have issued an Audit Report with unmodified opinion(s) on the audited Standalone Financial Results of the Company for the quarter and year ended on 31<sup>st</sup> March 2026.

This is for your information and records.

You are kindly requested to take the above information on your record.

Thanking You.

**For and on behalf of  
Brawn Biotech Limited**

**Rati Garg  
Chief Financial Officer**



**BRAWN BIOTECH LTD.**

**CIN NO.: L74899DL1985PLC022468**

**Regd. Office :** C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331

Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com)

**Works :** Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA

Email: [distribution@brawnlabs.in](mailto:distribution@brawnlabs.in) | Website : [www.brawngroup.in](http://www.brawngroup.in)

*...for better life*